White Paper
Assessing person-centered therapeutic innovations
Are usage experience and outcome benefits from person-centered therapeutic innovations appropriately valued?
Nov 14, 2019
Download

Follow-on drugs, drug plus drug combinations, drug reformulations, drug repositioning, drug plus digital applications and drug plus device combinations account for a significant proportion of medical innovations and have long been recognised as an integral part of the innovation pathway. They provide benefits for stakeholders across the healthcare system, such as patients and their caregivers, physicians and payers. They can also benefit the healthcare system through greater price competition resulting in cost savings.

DISCLAIMER: The research is sponsored by the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Contact Us